Palvella Therapeutics, Inc. (PVLA) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $126.31: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum.
Palvella Therapeutics is a clinical-stage biopharma developing topical therapies for rare skin diseases and vascular malformations using its QTORIN platform. Its lead product QTORIN rapamycin met its Phase 3 primary endpoint for microcystic lymphatic malformations in early 2026,... Read more
Sell if holding. Engine safety override at $126.31: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: RSI 49 mid-range, Bollinger mid-band. Score 4.7/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductQTORIN rapamycin10-K Item 1A: 'Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of QTORIN rapamycin'
Material Events(8-K, last 90d)
- 2026-04-13Item 5.02LOWJohn Doux, M.D. appointed to Board as Class III director effective April 13, 2026, filling a vacancy from Board size increase from 6 to 7. Board-certified dermatologist and healthcare investor. No reason for prior vacancy cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $126.31: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: RSI 49 mid-range, Bollinger mid-band. Prior stop was $117.29. Score 4.7/10, moderate confidence.
Take-profit target: $207.06 (+64.2% upside). Prior stop was $117.29. Stop-loss: $117.29.
Concentration risk — Product: QTORIN rapamycin; Quality below floor (1.9 < 4.0).
Palvella Therapeutics, Inc. trades at a P/E of N/A (forward -19.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts cover PVLA with a consensus score of 4.2/5. Average price target: $230.
What does Palvella Therapeutics, Inc. do?Palvella Therapeutics is a clinical-stage biopharma developing topical therapies for rare skin diseases and vascular...
Palvella Therapeutics is a clinical-stage biopharma developing topical therapies for rare skin diseases and vascular malformations using its QTORIN platform. Its lead product QTORIN rapamycin met its Phase 3 primary endpoint for microcystic lymphatic malformations in early 2026, with NDA submission planned for the second half of 2026.